马拉维洛克
变构调节
CCR5受体拮抗剂
趋化因子受体CCR5
C-C趋化因子受体6型
趋化因子受体
进入抑制剂
病毒进入
人类免疫缺陷病毒(HIV)
CXCR4型
化学
生物
趋化因子
细胞生物学
受体
病毒学
病毒复制
生物化学
病毒
作者
Qiuxiang Tan,Yun Zhu,Jian Li,Zhuxi Chen,Gye Won Han,Irina Kufareva,Tingting Li,Limin Ma,Gustavo Fenalti,Jing Li,Wenru Zhang,Xin Xie,Huaiyu Yang,Hualiang Jiang,Vadim Cherezov,Hong Liu,Raymond C. Stevens,Qiang Zhao,Beili Wu
出处
期刊:Science
[American Association for the Advancement of Science (AAAS)]
日期:2013-09-20
卷期号:341 (6152): 1387-1390
被引量:624
标识
DOI:10.1126/science.1241475
摘要
The CCR5 chemokine receptor acts as a co-receptor for HIV-1 viral entry. Here we report the 2.7 angstrom-resolution crystal structure of human CCR5 bound to the marketed HIV drug maraviroc. The structure reveals a ligand-binding site that is distinct from the proposed major recognition sites for chemokines and the viral glycoprotein gp120, providing insights into the mechanism of allosteric inhibition of chemokine signaling and viral entry. A comparison between CCR5 and CXCR4 crystal structures, along with models of co-receptor-gp120-V3 complexes, suggests that different charge distributions and steric hindrances caused by residue substitutions may be major determinants of HIV-1 co-receptor selectivity. These high-resolution insights into CCR5 can enable structure-based drug discovery for the treatment of HIV-1 infection.
科研通智能强力驱动
Strongly Powered by AbleSci AI